Kura Oncology Inc. (KURA)
Kura Oncology Statistics
Share Statistics
Kura Oncology has 80.78M shares outstanding. The number of shares has increased by 6% in one year.
| Shares Outstanding | 80.78M |
| Shares Change (YoY) | 6% |
| Shares Change (QoQ) | 3.85% |
| Owned by Institutions (%) | 90.77% |
| Shares Floating | 75.17M |
| Failed to Deliver (FTD) Shares | 2.35K |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 8.8M, so 11.32% of the outstanding shares have been sold short.
| Short Interest | 8.8M |
| Short % of Shares Out | 11.32% |
| Short % of Float | 11.43% |
| Short Ratio (days to cover) | 8.91 |
Valuation Ratios
The PE ratio is -4.31 and the forward PE ratio is -3.18. Kura Oncology's PEG ratio is 1.5.
| PE Ratio | -4.31 |
| Forward PE | -3.18 |
| PS Ratio | 13.93 |
| Forward PS | 0.6 |
| PB Ratio | 1.81 |
| P/FCF Ratio | 5.61 |
| PEG Ratio | 1.5 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Kura Oncology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.46, with a Debt / Equity ratio of 0.04.
| Current Ratio | 9.46 |
| Quick Ratio | 9.46 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.1 |
| Debt / FCF | 0.12 |
| Interest Coverage | -119.33 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $280.64K |
| Profits Per Employee | $-906.16K |
| Employee Count | 192 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 2.02M |
| Effective Tax Rate | -1.17% |
Stock Price Statistics
The stock price has increased by -66.34% in the last 52 weeks. The beta is 0.82, so Kura Oncology's price volatility has been higher than the market average.
| Beta | 0.82 |
| 52-Week Price Change | -66.34% |
| 50-Day Moving Average | 7.25 |
| 200-Day Moving Average | 13.71 |
| Relative Strength Index (RSI) | 38.78 |
| Average Volume (20 Days) | 1.56M |
Income Statement
In the last 12 months, Kura Oncology had revenue of 53.88M and earned -173.98M in profits. Earnings per share was -2.02.
| Revenue | 53.88M |
| Gross Profit | 53.88M |
| Operating Income | -193.19M |
| Net Income | -173.98M |
| EBITDA | -169.5M |
| EBIT | -170.35M |
| Earnings Per Share (EPS) | -2.02 |
Balance Sheet
The company has 224.46M in cash and 16.59M in debt, giving a net cash position of 207.87M.
| Cash & Cash Equivalents | 224.46M |
| Total Debt | 16.59M |
| Net Cash | 207.87M |
| Retained Earnings | -895.42M |
| Total Assets | 760.16M |
| Working Capital | 666.12M |
Cash Flow
In the last 12 months, operating cash flow was 134.32M and capital expenditures -472K, giving a free cash flow of 133.84M.
| Operating Cash Flow | 134.32M |
| Capital Expenditures | -472K |
| Free Cash Flow | 133.84M |
| FCF Per Share | 1.55 |
Margins
Gross margin is 100%, with operating and profit margins of -358.55% and -322.89%.
| Gross Margin | 100% |
| Operating Margin | -358.55% |
| Pretax Margin | -319.15% |
| Profit Margin | -322.89% |
| EBITDA Margin | -314.57% |
| EBIT Margin | -358.55% |
| FCF Margin | 248.4% |
Dividends & Yields
KURA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for KURA is $28, which is 374.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $28 |
| Price Target Difference | 374.6% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | -0.48 |
| Piotroski F-Score | 5 |